Research Article

The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series

Table 1

Baseline characteristics.

PatientWeight (kg), height (cm), BMI (kg/m2)Number of comorbidities, number of cardiovascular and thrombotic risk factorsAge at ITP diagnosis (years)Type of ITP at start of fostamatinibSteroid exposure, IVIG, splenectomy, other previous ITP treatmentsPrior unique treatmentsDuration of ITP diagnosis prior to fostamatinib (years)

1
94F Caucasian
64, 167, 22.96
1
72ChronicDex and pred, no, no, azathioprine222.6
2
94M Caucasian
63.4, 158, 25.411
3
94PersistentDex, yes, no, none20.2
3
80F Caucasian
64.6, 166, 23.414
5
80PersistentDex and pred, yes, no, none20.5
4
78F Caucasian
77, 155, 32.03
3
73ChronicPred, yes, no, azathioprine, TPO-RA45.4
5
78M Caucasian
70, 169, 24.54
2
63ChronicDex and pred, yes, yes, azathioprine, rituximab, TPO-RA614.7
6
94F Caucasian
65, 165, 23.96
1
65ChronicPred, no, no, none129.8
7
80M Caucasian
82, 190, 22.72
1
80PersistentDex and pred, no, no, none10.4

Dex, dexamethasone; pred, prednisone; TPO-RA, thrombopoietin receptor agonist; cardiovascular and thrombotic risk factors including known thrombosis, coronary artery disease, strokes, or transient ischaemic attacks, hypertension, diabetes, dyslipidemia, and smoking.